Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm

REFERENCES

• Cook DA. Mechanisms of cerebral vasospasm in subarachnoid haemorrhage. Pharmacol Ther 1995; 66: 259–284
   PubMed Web of Science ®Google Scholar
• Rosenorn J, Eskesen V, Schmidt K, et al. Clinical features and outcome in 1076 patients with ruptured intracranial saccular aneurysms: A prospective consecutive study. Br I Neurosurg 1987; 1: 33–45
   PubMedGoogle Scholar
• Saveland H, Sonesson B, Ljunggren B, et al. Outcome evaluation following subarachnoid hemorrhage. Neurosurg 1986; 64: 191–196
   Web of Science ®Google Scholar
• Dumont AS, Dumont RJ, Chow MM, et al. Cerebral vasospasm after subarachnoid hemorrhage: Putative role of inflammation. Neurosurgery 2003; 53: 123–133
   PubMed Web of Science ®Google Scholar
• Hino A, Tokuyama Y, Weir B, et al. Changes in endothelial nitric oxide synthase mRNA during vasospasm after subarachnoid hemorrhage in monkeys. Neurosurgery 1996; 39: 562–567
   PubMed Web of Science ®Google Scholar
• Medele RJ, Stummer W, Reulen Hi, et al. Evidence for peroxidative damage by nitric oxide in experimental chronic cerebral vasospasm. Neurol Res 1996; 18: 277–280
   PubMed Web of Science ®Google Scholar
• Kasuya H, Weir BK, Nakane M, et al. Nitric oxide synthase and guanylate cyclase levels in canine basilar artery after subarach-noid hemorrhage. J Neurosurg 1995; 82: 250–255
   PubMed Web of Science ®Google Scholar
• Clozel M, Watanabe H. BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci 1993; 52: 825–834
   PubMed Web of Science ®Google Scholar
• Cosentino F, McMahon EG, Carter JS, et al. Effect of endothelin-A-receptor antagonist B0-123 and phosphoramidon on cerebral vasospasm. J Cardiovasc Pharmacol 1993; 22 (Suppl. 8): S332—S335
   Google Scholar
• Feger GI, Schilling L, Ehrenreich H, et al. Endothelin-induced contraction and relaxation of rat isolated basilar artery: Effect of BQ-123. J Cereb Blood Flow Metab 1994; 14: 845–852
   PubMed Web of Science ®Google Scholar
• Foley PL, Cancer HH, Kassell NF, et al. Reversal of subarachnoid hemorrhage-induced vasoconstriction with an endothelin recep-tor antagonist. Neurosurgery 1994; 34: 108–113
   PubMed Web of Science ®Google Scholar
• Hino A, Weir BKA, Macdonald RL, et al. Prospective, rando-mized, double-blind trial of BQ123 and bosentan for prevention of vasospasm following subarachnoid hemorrhage in monkeys. I Neurosurg 1995; 83: 503–509
   PubMed Web of Science ®Google Scholar
• Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: Three structurally and pharmacologically distinct isopep-tides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86: 2863–2867
   PubMed Web of Science ®Google Scholar
• Inoue A, Yanagisawa M, Takuwa Y, et al. The human preproendothelin 1 gene. Complete nucleotide sequence and regulation of expression. I Biol Chem 1989; 264: 14954–14959
   Google Scholar
• Matsumura Y, Ikegawa R, Suzuki Y, et al. Phosphoramidon prevents cerebral vasospasm following subarachnoid hemorrhage in dogs: The relationship to endothelin-1 levels in the cerebrosp-inal fluid. Life Sci 1991; 49: 841–848
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Ikegawa R, Tsukahara Y, et al. Conversion of big endothelin-1 to endothelin-1 by two types of met al loproteinases derived from porcine aortic endothelial cells. FEBS Lett 1990; 272: 166–170
   PubMed Web of Science ®Google Scholar
• Nirei H, Hamada K, Shoubo M, et al. An endothelin ETA receptor antagonist, FR 139317, ameliorates cerebral vasospasm in dogs. Life Sci 1993; 52: 1869–1874
   PubMed Web of Science ®Google Scholar
• Shinyama H, Uchida T, Kido H, et al. Phosphoramidon inhibits the conversion of intracisternally administered big endothelin-1 to endothelin-1. Biochem Biophys Res Commun 1991; 178: 24–30
   PubMed Web of Science ®Google Scholar
• Suzuki H, Sato S, Suzuki Y, et al. Increased endothelin concentration in CSF from patients with subarachnoid hemor-rhage. Acta Neurol Scand 1990; 81: 553–554
   PubMed Web of Science ®Google Scholar
• Yamaura I, Tani E, Maeda Y, et al. Endothelin-1 of canine basilar artery in vasospasm. I Neurosurg 1992; 6: 99–105
   Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, et al. Novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–415
   PubMed Web of Science ®Google Scholar
• Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373–376
   PubMed Web of Science ®Google Scholar
• Arai H, Hon i S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730–732
   PubMed Web of Science ®Google Scholar
• Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature 1990; 348: 732–735
   PubMed Web of Science ®Google Scholar
• Goto K, Kasuya, Matsuki N, et al. Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca2+ channel in vascular smooth muscle. Proc Natl Acad Sci USA 1989; 86: 3915–3918
   PubMed Web of Science ®Google Scholar
• Ohnaka K, Takayanagi R, Yamauchi T, et al. Identification and characterization of endothelin converting activity in cultured bovine endothelial cells. Biochem Biophys Res Commum 1990; 168: 1128–1136
   PubMed Web of Science ®Google Scholar
• Okada K, Miyazaki Y, Takada J, et al. Conversion of big endothelin-1 by membrane-bound met al loendopeptidase in cultured bovine endothelial cells. Biochem Biophys Res Commun 1990; 171:1192–1198
   PubMed Web of Science ®Google Scholar
• Kashiwabara T, Inagaki Y, Ohta H, et al. Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo. FEBS Lett 1989; 247: 73–76
   PubMed Web of Science ®Google Scholar
• Goto K, Hama H, Kasuya Y. Molecular pharmacology and pathophysiological significance of endothelin. Jpn I Pharmacol 1996; 72: 261–290
   PubMedGoogle Scholar
• Opgenorth Ti, Wu-Wong JR, Shiosaki K. Endothelin-converting enzymes. FASEB J 1992; 6: 2653–2659
   PubMed Web of Science ®Google Scholar
• Sakurai T, Yanagisawa M, Inoue A, et al. cDNA cloning, sequence analysis and tissue distribution of rat preproendothelin-1 mRNA. Biochem Biophys Res Commun 1991; 175: 44–47
   PubMed Web of Science ®Google Scholar
• Cocks TM, Broughton A, Dib M, et al. Endothelin is blood vessel selective: Studies on a variety of human and dog vessels in vitro and on regional blood flow in the conscious rabbit. Clin Exp Pharmacol Physiol 1989; 16: 243–246
   PubMed Web of Science ®Google Scholar
• Cocks TM, Faulkner NL, Sudhir K, et al. Reactivity of endothelin-1 on human and canine large veins compared with large arteries in vivo. Eur J Pharmacol 1989; 171: 17–24
   PubMed Web of Science ®Google Scholar
• Seifert V, Löffler BM, Zimmerman M, et al. Endothelin concentrations in patients with aneurysmal subarachnoid hemor-rhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. I Neurosurg 1995; 8: 55–62
   Web of Science ®Google Scholar
• Suzuki R, Masaoka H, Hirata Y, et al. The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. I Neurosurg 1992; 77: 96–100
   PubMed Web of Science ®Google Scholar
• Masaoka H, Suzuki R, Hirata Y, et al. Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet 1989; 2: 1402
   PubMed Web of Science ®Google Scholar
• Fujimori A, Yanagisawa M, Saito A, et al. Endothelin in plasma and cerebrospinal fluid of patients with subarachnoid hemor-rhage. Lancet 1990; 336: 633
   PubMed Web of Science ®Google Scholar
• Kraus GE, Bucholz RD, Yoon KVV, et al. Cerebrospinal fluid endothelin-1 and endothelin-3 levels in normal and neurological patients: A clinical study and literature review. Surg Neurol 1991; 35: 20–29
   PubMedGoogle Scholar
• Suzuki H, Sato S, Suzuki Y, et al. Endothelin immunoreactivity in cerebrospinal fluid of patients with subarachnoid haemorrhage. Ann Med 1990; 22: 233–236
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Lange M, Near KA, et al. Long term monitoring of immunoreactive endothelin-1 and endothelin-3 in ventricular cerebrospinal fluid, plasma, and 24-h urine of patients with subarachnoid hemorrhage. Res Exp Med (Berl) 1992; 192: 257–268
   PubMedGoogle Scholar
• Mascia L, Fedorko L, Stewart DJ, et al. Temporal relationship between endothelin-1 concentrations and cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Stroke 2001; 32: 1185-1190
   Google Scholar
• Suzuki K, Meguro K, Sakurai T, et al. Endothelin-1 concentration increases in the cerebrospinal fluid in cerebral vasospasm caused by subarachnoid hemorrhage. Surg Neurol 2000; 53: 131–135
   PubMedGoogle Scholar
• Juvela S. Plasma endothelin concentrations after subarachnoid hemorrhage. I Neurosurg 2000; 92: 390–400
   PubMed Web of Science ®Google Scholar
• Zimmermann M. Endothelin in cerebral vasospasm. Clinical and experimental results. I Neurosurg Sci 1997; 41: 139–151
   PubMedGoogle Scholar
• Kim JM, Bak KH, Kim CH, et al. The role of endothelin-1 as predictor of the symptomatic vasospasm in acute stage of subarachnoid haemorrhage. Acta Neurochir Suppl 2001; 77: 77–79
   PubMedGoogle Scholar
• Juvela S. Plasma endothelin and big endothelin concentrations and serum endothelin-converting enzyme activity following aneurysmal subarachnoid hemorrhage. I Neurosurg 2002; 97: 1287–1293
   PubMed Web of Science ®Google Scholar
• Menon DK, Day D, Kuc RE, et al. Arteriojugular endothelin-1 gradients in aneurysmal subarachnoid haemorrhage. Clin Sci (Lond) 2002; 103 (Suppl. 48): 5399—S403
   Google Scholar
• Asano T, Ikegaki I, Suzuki Y, et al. Endothel in and the production of cerebral vasospasm in dogs. Biochem Biophys Res Commun 1989; 159: 1345–1351
   PubMed Web of Science ®Google Scholar
• Ide K, Yamakawa K, Nakagomi T, et al. The role of endothelin in the pathogenesis of vasospasm following subarachnoid haemor-rhage. Neurol Res 1989; 11: 101–104
   PubMedGoogle Scholar
• Kobayashi H, Hayashi M, Kobayashi S, et al. Effect of endothelin on the canine basilar artery. Neurosurgery 1990; 27: 357–361
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Hayashi M, Kobayashi S, et al. Cerebral vasospasm and vasoconstriction caused by endothelin. Neurosurgery 1991; 28: 673–679
   PubMed Web of Science ®Google Scholar
• Mima T, Yanagisawa M, Shigeno T, et al. Endothelin acts in feline and canine cerebral arteries from the adventitial side. Stroke 1989; 20: 1553–1556
   PubMed Web of Science ®Google Scholar
• Tanoi C, Suzuki Y, Shibuya M, et al. Mechanism of the enhanced vasoconstrictor responses to endothelin-1 in canine cerebral arteries. J Cereb Blood Flow Metab 1991; 11:371–379
   PubMed Web of Science ®Google Scholar
• Zubkov AY, Rollins KS, Parent AD, et al. Mechanism of endothelin-1—induced contraction in rabbit basilar artery. Stroke 2000; 31: 526–533
   PubMed Web of Science ®Google Scholar
• Hamann G, Isenberg E, Strittmatter M, et al. Absence of elevation of big endothelin in subarachnoid hemorrhage. Stroke 1993; 24: 383–386
   PubMed Web of Science ®Google Scholar
• Hino A, Tokuyama Y, Kobayashi M, et al. Increased expression of endothelin B receptor mRNA following subarachnoid hemor-rhage in monkeys.] Cereb Blood Flow Metab 1996; 16: 688–697
   PubMed Web of Science ®Google Scholar
• Pluta RM, Broock RJ, Afshar JK, et al. Source of endothelin-1 release into cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg 1997; 87: 287–293
   PubMed Web of Science ®Google Scholar
• Nishizawa S, Chen D, Yokoyama T, et al. Endothel in-1 initiates the development of vasospasm after subarachnoid haemorrhage through protein kinase C activation, but does not contribute to prolonged vasospasm. Acta Neurochir (Wien) 2000; 142: 1409–1415
   PubMed Web of Science ®Google Scholar
• Hansen-Schwartz J. Receptor changes in cerebral arteries after subarachnoid haemorrhage. Acta Neurol Scand 2004; 109: 33–44
   PubMed Web of Science ®Google Scholar
• Hansen-Schwartz J, Hoel NL, Zhou M, et al. Subarachnoid hemorrhage enhances endothelin receptor expression and func-tion in rat cerebral arteries. Neurosurgery 2003; 52: 1188–94
   PubMed Web of Science ®Google Scholar
• Clozel M, Breu V, Burn i K, et al. Pathophysiological role ofendothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993; 365: 759–761
   PubMed Web of Science ®Google Scholar
• Zuccarello M, Boccaletti R, Roman A, et al. Endothel in B receptor antagonists attenuate subarachnoid hemorrhage-induced cerebral vasospasm. Stroke 1998; 29: 1924–1929
   PubMed Web of Science ®Google Scholar
• Ohkuma H, Parney I, Megyesi J, et al. Antisense preproendothel in-oligoDNA therapy for vasospasms in a canine model of subarachnoid hemorrhage. J Neurosurg 1999; 90: 1105–1114
   PubMed Web of Science ®Google Scholar
• De Lombaeff S, Ghai RD, Jeng AY, et al. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme. Biochem Biophys Res Commun 1994; 204: 407–412
   PubMed Web of Science ®Google Scholar
• Caner HH, Kwan AL, Arthur A, et al. Systemic administration of an inhibitor of endothelin-converting enzyme for attenuation of cerebral vasospasm following experimental subarachnoid hemor-rhage. J Neurosurg 1996; 85: 917–922
   PubMed Web of Science ®Google Scholar
• Kwan AL, Bavbek M, Jeng AY, et al. Prevention and reversal of cerebral vasospasm by an endothelin-converting enzyme inhi-bitor, CGS 26303, in an experimental model of subarachnoid hemorrhage. J Neurosurg 1997; 87: 281–286
   PubMed Web of Science ®Google Scholar
• Kwan AL, Lin CL, Chang CZ, et al. Continuous intravenous infusion of CGS 26303, an endothelin-converting enzyme inhibitor, prevents and reverses cerebral vasospasm after experi-mental subarachnoid hemorrhage. Neurosurgery 2001; 49: 422–427
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Jung C, Raabe A, et al, Inhibition of endothelin-converting enzyme activity in the basilar artery. Neurosurgery 2001: 48: 902–910
   PubMed Web of Science ®Google Scholar
• Morita A, Nomizu M, Pkitsu M, et al. D-Va122 containing human big endothelin-1 analog, [D-Va122]big ET-1[16-38], inhibits the endothelin converting enzyme. FEBS Lett 1994; 353: 84–88
   PubMed Web of Science ®Google Scholar
• Josko J, Hendryk S, Jedrzejowska-Szypulka H, et al. Reactivity of cerebral arteries after subarachnoid hemorrhage in rats after phosphoramidon administered. Med Sci Monit 2000; 6:976–980
   PubMedGoogle Scholar
• Shigeno T, Mima T, Yanagisawa M, et al. Possible role of endothelin in the pathogenesis of cerebral vasospasm. J Cardiovasc Pharmacol 1991; 17: S480—S483
   PubMed Web of Science ®Google Scholar
• Kwan AL, Bavbek M, Jeng AY, et al. Attenuation of experimental subarachnoid hemorrhage-induced cerebral vasospasm by CGS 26303, an endothelin-converting enzyme inhibitor. J Cardiovasc Pharmacol 1998; 31 (Suppl. 1): S320—S323
   Google Scholar
• Vatter H, Schilling L, Schmiedek P, et al. Evidence for functional endothelin-converting enzyme activity in isolated rat basilar artery: Effect of inhibitors. J Cardiovasc Pharmacol 1998; 31(Suppl. 1): S64—S67
   Google Scholar
• Onoda K, Ono S, Ogihara K, et al. Inhibition of vascular contraction by intracisternal administration of preproendothel in-1 mRNA antisense oligoDNA in a rat experimental vasospasm model. J Neurosurg 1996; 85: 846–852
   PubMed Web of Science ®Google Scholar
• Mostafa MG, Mima T, Taniguchi T, et al. Doxorubicin, an RNA synthesis inhibitor, prevents vasoconstriction and inhibits aber-rant expression of endothelin-1 in the cerebral vasospasm model of the rat. Neurosci Lett 2000; 283: 197–200
   PubMed Web of Science ®Google Scholar
• Mima T, Mostafa MG, Mori K. Therapeutic dose and timing of administration of RNA synthesis inhibitors for preventing cerebral vasospasm after subarachnoid hemorrhage. Acta Neurochir Suppl (Wien) 1997; 70: 65–67
   PubMedGoogle Scholar
• Shigeno T, Mima T, Yanagisawa M, et al. Prevention of cerebral vasospasm by actinomycin. J Neurosurg 1991; 74: 940–943
   PubMed Web of Science ®Google Scholar
• Kwan AL, Lin CL, Chang CZ, et al. Oral administration of an inhibitor of endothelin-converting enzyme attenuates cerebral vasospasm following experimental subarachnoid hemorrhage. Clin Sci (Lond) 2002; 103 (Suppl. 48): S414—S417
   Google Scholar
• Kwan AL, Lin CL, ChangCZ, et al. Attenuation of SAH-induced cerebral vasospasm by a selective ECE inhibitor. Neuroreport 2002; 13: 197–199
   PubMed Web of Science ®Google Scholar
• Shaw MD, Vermeulen M, Murray GD, et al. Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subar-achnoid hemorrhage: A report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosurg 2000; 93: 992–997
   PubMed Web of Science ®Google Scholar
• Josko J, Hendryk S, Jedrzejowska-Szypulka H, et al. Effect of endothelin-1 receptor antagonist BQ-123 on basilar artery diameter after subarachnoid hemorrhage (SAH) in rats. J Physiol Pharmacol 2000; 51: 241–249
   PubMed Web of Science ®Google Scholar
• Ogihara K, Barnanke DH, Zubkov AY, et al. Effect of endothelin receptor antagonists on non-muscle matrix compaction in a cell culture vasospasm model. Neurol Res 2000; 22: 209–214
   PubMed Web of Science ®Google Scholar
• Kikkawa K, Saito A, Iwasaki H, et al. Prevention of cerebral vasospasm by a novel endothelin receptor antagonist, TA-0201. J Cardiovasc Pharmacol 1999; 34: 666–673
   PubMed Web of Science ®Google Scholar
• Wanebo JE, Arthur AS, Louis HG, et al. Systemic administration of the endothel in-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemor-rhage: Dose study and review of endothelin-based therapies in the literature on cerebral vasospasm. Neurosurgery 1998; 43: 1409–1418
   PubMed Web of Science ®Google Scholar
• Kita T, Kubo K, Hiramatsu K, et al. Profiles of an intravenously available endothelin A-receptor antagonist, S-0139, for prevent-ing cerebral vasospasm in a canine two-hemorrhage model. Life Sci 1998; 63: 305–315
   PubMed Web of Science ®Google Scholar
• Kim CJ, Bassiouny M, Macdonald RL, et al. Effect of BQ-123 and tissue plasminogen activator on vasospasm after subarachnoid hemorrhage in monkeys. Stroke 1996; 27: 1629–1633
   PubMed Web of Science ®Google Scholar
• Zuccarello M, Soattin GB, Lewis Al, et al. Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists. J Neurosurg 1996; 84: 503–507
   PubMed Web of Science ®Google Scholar
• Itoh S, Sasaki T, Asai A, et al. Prevention of delayed vasospasm by an endothelin ETA receptor antagonist, BQ-123: Change of ETA receptor mRNA expression in a canine subarachnoid hemorrhage model. J Neurosurg 1994; 81: 759–764
   PubMed Web of Science ®Google Scholar
• Zuccarello M, Lewis Al, Rapoport RM. Endothelin ETA and ETB receptors in subarachnoid hemorrhage-induced cerebral vasos-pasm. Eur Pharmacol 1994; 259: R1—R2
   PubMed Web of Science ®Google Scholar
• Macdonald RL, Johns L, Lin G, et al. Prevention of vasospasm after subarachnoid hemorrhage in dogs by continuous intrave-nous infusion of PD156707. Neurol Med Chir (Tokyo) 1998; 38: 138-145
   Google Scholar
• Roux S, Breu V, Giller T, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: General pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997; 283: 1110–1118
   PubMed Web of Science ®Google Scholar
• Barone FC, Willette RN, Yue TL, et al. Therapeutic effects of endothelin receptor antagonists in stroke. Neurol Res 1995; 17: 259–264
   PubMed Web of Science ®Google Scholar
• Gross PM, Weaver DF, Ho LT, et al. FR139317, a specific ETA-receptor antagonist, inhibits cerebral activation by intraventricu-lar endothel in-1 in conscious rats. Neuropharmacology 1994; 33: 1155–1166
   PubMed Web of Science ®Google Scholar
• Xu D, Emoto N, Giaid A, et al. ECE-1: A membrane-bound met al loprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994; 78: 473–485
   PubMed Web of Science ®Google Scholar
• Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive met al loprotease with acidic pH optimum. J Biol Chem 1995; 270: 15262–15268
   PubMed Web of Science ®Google Scholar
• Schmidt M, Kroger B, Jacob E, et al. Molecular characterization of human and bovine endothelin converting enzyme (ECE-1). FEBS Lett 1994; 356: 238–243
   PubMed Web of Science ®Google Scholar
• Shimada K, Takahashi M, Tanzawa K. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem 1994; 269: 18275–18278
   PubMed Web of Science ®Google Scholar
• Kundu GC, Wilson IB. Endothelin-converting enzyme: The binding of met al ions. Int J Pept Protein Res 1993; 42: 64–67
   PubMedGoogle Scholar
• Davenport AP, Kuc RE, Plumpton C, et al. Endothelin-converting enzyme in human tissues. Histochem J 1998; 30: 359–374
   Google Scholar
• Azarani A, Boileau G, Crine P. Recombinant human endothelin-converting enzyme ECE-1b is located in an intracellular compartment when expressed in polarized Madin-Darby canine kidney cells. Biochem] 1998; 333: 439–448
   Google Scholar
• Turner AJ, Barnes K, Schweizer A, et al. Isoforms of endothelin-converting enzyme: Why and where? Trends Pharmacol Sci 1998; 19: 483–486
   PubMed Web of Science ®Google Scholar
• Jeng AY, De Lombaert S. Endothelin-converting enzyme inhibi-tors. Curr Pharm Des 1997; 3: 597–614
   Web of Science ®Google Scholar
• Löffler BM. ACE, NEP, ECE-1: Selective and combined inhibition. Curr Opin Cardiovasc Pulm Renal Invest Drugs 1999; 1: 352–364
   Google Scholar
• Ruskoaho H. Atrial natriuretic peptide: Synthesis, release, and metabolism. Pharmacol Rev 1992; 44: 479–602
   PubMed Web of Science ®Google Scholar
• Masaki T, Yanagisawa M, Goto K. Physiology and pharmacology of endothel ins. Med Res Rev 1992; 12: 391–421
   PubMed Web of Science ®Google Scholar
• Hoang MV, Turner AJ. Novel activity of endothelin-converting enzyme: Hydrolysis of bradykinin. Biochem] 1997; 327: 23–26
   Google Scholar
• Löffler BM. Endothelin-converting enzyme inhibitors: Current status and perspectives. J Cardiovasc Pharmacol 2000; 35 (Suppl. 2): S79—S82
   Google Scholar
• Cheng C, Onishi K, Ohte N. Functional effects of endogenous bradykinin in congestive heart failure. J Am Coll Cardiol 1998; 31: 1679–1686
   PubMed Web of Science ®Google Scholar
• Kukkola PJ, Savage P, Sakane Y, et al. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three met alloproteases: Endothel in-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.] Cardiovasc Pharmacol 1995; 26 (Suppl. 3): S65—S68
   Google Scholar
• Ksander GM, Savage P, Trapani AJ, et al. Benzofused macrocyclic lactams as triple inhibitors of endothel in-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1998; 31 (Suppl. 1): S71—S73.
   Google Scholar
• McMahon EG, Palomo MA, Moore WM, et al. Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro. Proc Natl Acad Sci USA 1991; 88: 703–707
   PubMed Web of Science ®Google Scholar
• Kwan AL, Lin CL, Chang CZ, et al. Effects of endothelin-converting enzyme inhibitors on hemolysate-induced morpholo-gical changes and production of endothelin-1 in bovine cerebrovascular endothelial cells. J Cardiovasc Pharmacol 2000; 36 (Suppl. 1): S160—S162
   Google Scholar
• Trapani, AJ, De Lombaert S, Kuzmich S, et al, Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11. J Cardiovasc Pharmacol 1995; 26 (Suppl. 3): 569-571
   Google Scholar
• Trapani, AJ, De Lombaert, S, Beil ME, et al. CGS 34043: A non-peptidic, potent and long-acting dual inhibitor of endothelin-converting enzyme-1 and neutral endopeptidase 24.11. Life Sci 2000; 67: 1025–1033
   PubMed Web of Science ®Google Scholar
• Keller PM, Lee CP, Fenwick AE, et al. Endothelin-converting enzyme: Substrate specificity and inhibition by novel analogs of phosphoramidon. Biochem Biophys Res Commun 1996; 223: 372–378
   PubMed Web of Science ®Google Scholar
• Fukami T, Hayama T, Amano Y, et al. Aminophosphonate endothelin converting enzyme inhibitors: Potency-enhancing and selectivity-improving modifications of phosphoramidon. Bioorg Med Chem Lett 1994; 4: 1257–1262
   Web of Science ®Google Scholar
• Norcini G, Morazzoni G, Pocchiari F, et al. Novel selective thiol inhibitors of neutral endopeptidase containing heterocycles at P'2 position. J Enzyme Inhib 1997; 12: 155–160
   PubMed Web of Science ®Google Scholar
• Meil J, Rupp H, Thormählen D, et al. In-vivo results with SLV 306, an orally active inhibitor of NEP and ECE. Naunyn-Schmiedeberg's Arch Pharmacol 1998; 358 (Suppl. 1): R514
   Google Scholar
• Meil J, Wurl M, Thormählen D, et al. Pharmacology of the active metabolite of SLV 306-A mixed inhibitor of NEP and ECE. Naunyn-Schmiedeberg's Arch Pharmacol 1998; 358 (Suppl. 1): R513
   Google Scholar
• Andrews P, Papadakis N, Gavras H. Reversal of experimental acute cerebral vasospasm by angiotensin converting enzyme inhibition. Stroke 1982; 13: 480–483
   PubMed Web of Science ®Google Scholar
• Gavras H, Andrews P, Papadakis N. Reversal of experimental delayed cerebral vasospasm by angiotensin-converting enzyme inhibition.]Neurosurg 1981; 55: 884–888
   PubMed Web of Science ®Google Scholar
• Iplikcioglu AC, Bayer MA, Say A, et al. Angiotensin-converting enzyme inhibitor cilazapril prevents chronic morphologic vasospasm in rat. Surg Neurol 1994; 41: 294–298
   PubMed Web of Science ®Google Scholar
• Honda Y, Minato H, Fujitani B, et al. Alacepril, an angiotensin-converting enzyme inhibitor, prevents cerebral vasospasm in subarachnoid hemorrhage model in rats. Methods Find Exp Clin Pharmacol 1997; 19: 699–706
   PubMed Web of Science ®Google Scholar
• Mombouli JV, Vanhoutte PM. Endothelial dysfunction: From physiology to therapy. J Mol Cell Cardiol 1999; 3: 61–74
   Web of Science ®Google Scholar
• McKittrick BA, Stamford AW, Weng X, et al. Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopepti-dase 24.11. Bioorg Med Chem Lett 1996; 6: 1629–1634
   Web of Science ®Google Scholar
• Battistini B, Jeng AY. Endothelin-converting enzyme inhibitors and their effects. Handb Exp Pharmocol 2001; 152: 155–208
   Google Scholar
• Gardiner SM, Kemp PA, Bennett T. Effects of the neutral endopeptidase inhibitor, SQ 28,603, on regional haemodynamic responses to atrial natriuretic peptide or preendothel in-1 [1-381 in conscious rats. Br] Pharmacol 1992; 106: 180–186
   PubMedGoogle Scholar
• Mattera GG, Eglezos A, Renzetti AR, et al. Comparison of the cardiovascular and neural activity of endothelin-1,2 and -3 and respective proendothelins: Effects of phosphoramidon and thiorphan. Br] Pharmacol 1993; 110: 331–337
   PubMed Web of Science ®Google Scholar
• Tsurumi Y, Ohhata N, Iwamoto T, et al. WS79089A, B and C, new endothelin converting enzyme inhibitors isolated from Streptosporangium roseum. No. 79089. Taxonomy, fermenta-tion, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo) 1994; 47: 619–630
   PubMed Web of Science ®Google Scholar
• Tsurumi Y, Ueda H, Hayashi K, et al. W575624 A and B, new endothelin converting enzyme inhibitors isolated from Saccharothrix sp. No. 75624. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo) 1995; 48: 1066–1072
   PubMed Web of Science ®Google Scholar
• Umekawa K, Hasegawa H, Tsutsumi Y, et al. Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin convert-ing enzyme. Jpn J Pharmacol 2000; 84: 7–15
   PubMedGoogle Scholar
• Ahn K, Sisneros AM, Herman SB, et al. Novel selective quinazoline inhibitors of endothelin converting enzyme-1. Biochem Biophys Res Commun 1998; 243: 184–190
   PubMed Web of Science ®Google Scholar
• Jeng AY, De Lombaert S, Beil ME, et al. Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 350664 Cardiovasc Pharmacol 2000; 36 (Suppl. 1): S36—S39
   Google Scholar